Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors.

ABSTRACT: Prognostic studies can provide important information about disease biology and improve the use of biomarkers to optimize treatment decisions.

Methods

A total of 199 patients with advanced melanoma treated with BRAF + MEK inhibitors were included in our single-center retrospective study. We analyzed the risk of progression and death using multivariate Cox proportional hazard models. The predictive effect of prognostic factors on progression-free survival (PFS) was evaluated in ROC analysis.

Results

We found that primary tumor localization, Clark level, pT category, baseline M stage and baseline serum S100B are independent and significant prognostic factors for PFS. The discriminative power of the combination of these factors was excellent for predicting 18 month PFS (AUC 0.822

SUBMITTER: Janka EA 

PROVIDER: S-EPMC11393897 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature